Mr. Andre Larente reports

DIAGNOS PROVIDES AN UPDATE ON STOCK WARRANTS

Diagnos Inc. has provided an update on the stock warrants that were exercised and that have expired in the last two months, as well as the outstanding balance.

During the period, 3,218,333 stock warrants were exercised for gross proceeds of $1,287,333.

During the period, the stock warrants listed in an attached table have expired.

As at the date of this news release, the stock warrants listed in another attached table are outstanding and can be exercised at the price of 40 cents per common share.

Diagnos would like to thank the shareholders for their continuous support.

About Diagnos Inc.

Diagnos is a public Canadian corporation dedicated to the early detection of critical eye-related health problems. Diagnos manufactures CARA System, a software platform that assists health specialists in the detection of retinal eye pathologies. CARA System is currently licensed for commercialization in Canada and Saudi Arabia. By developing innovative products based on AI (artificial intelligence) technologies, Diagnos's solutions provide health care clinicians with valuable information that refines diagnostic accuracy, streamlines workflows and improves patient outcomes.

We seek Safe Harbor.